Sulfadoxine- pyrimethamine+ amodiaquine dispersible

Supyra®
S Kant
Paediatric formulation
Intermittent preventative treatment (TPP-1)

Sulfadoxine- pyrimethamine+ amodiaquine dispersible

Access
-
Approved
Therapeutic indication

  • Seasonal Malaria chemoprevention (SMC) for children 3 to 59 months in eligible regions (Sahel region in Sub-Saharan Africa)
Dosing

  • Once daily for 3 days (amodiaquine) and one day (sulfadoxine-pyrimethamine), administered in monthly cycles for 4 months
Efficacy

  • 75% reduction in malaria episodes in pivotal trials
Key features

  • Recommended by WHO for the prevention of malaria in children in areas of high seasonal malaria transmission

  • 2-year shelf life
Challenges

  • Drug distribution to healthy subjects mainly via door-to-door campaigns
Status
  • WHO prequalification obtained in April 2021
  • 2nd taste-masked and dispersible SPAQ formulation prequalified by WHO
  • Registered in 6 countries; ongoing in 5 other countries
  • 18 million treatments delivered in 2021
Next milestone
  • Validation of dose and development of packaging or formulation  for children from 5-10 years
  • Seasonality stratification in all countries to define the number of rounds of SMC needed 
  • Adoption of a fifth monthly round of treatment in areas with longer seasonal transmission
  • Adoption in areas outside of the Sahel region
Project Director

  • Dr André-Marie Tchouatieu